Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
28.79%
0%
28.79%
6 Months
49.34%
0%
49.34%
1 Year
24.38%
0%
24.38%
2 Years
17.31%
0%
17.31%
3 Years
-21.59%
0%
-21.59%
4 Years
-39.35%
0%
-39.35%
5 Years
-34.77%
0%
-34.77%
BB Biotech AG for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-23.70%
EBIT Growth (5y)
-35.39%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
0.07%
Dividend Payout Ratio
130.04%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
8.21%
Valuation key factors
Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
1.17
EV to EBIT
4.13
EV to EBITDA
4.13
EV to Capital Employed
-145.26
EV to Sales
5.08
PEG Ratio
0.21
Dividend Yield
4.62%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
4.12%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
-20.40
21.00
-197.14%
Operating Profit (PBDIT) excl Other Income
-94.40
-87.10
-8.38%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-100.20
-87.10
-15.04%
Operating Profit Margin (Excl OI)
0.00%
-4,136.80%
413.68%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -197.14% vs 2,433.33% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -15.04% vs -545.19% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
62.10
-17.30
458.96%
Operating Profit (PBDIT) excl Other Income
76.40
-206.10
137.07%
Interest
0.50
0.40
25.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
75.90
-206.60
136.74%
Operating Profit Margin (Excl OI)
1,230.30%
0.00%
123.03%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 458.96% vs 38.87% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 136.74% vs 42.26% in Dec 2023
About BB Biotech AG 
BB Biotech AG
Finance
BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.
Company Coordinates 
Company Details
Schwertstrasse 6 , SCHAFFHAUSEN None : 8200
Registrar Details






